BIOMAT Database Logo BIOMAT Database Logo

Islet allotransplantation in type I diabetic patients: effects of islet cell number on clinical outcome. 1996

A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Department of General Surgery, San Raffaele Scientific Institute, University of Milan, Italy.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D011182 Postoperative Care The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed) Care, Postoperative,Postoperative Procedures,Procedures, Postoperative,Postoperative Procedure,Procedure, Postoperative
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson

Related Publications

A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Islet allotransplantation in type 1 diabetic patients.
June 2003, Minerva endocrinologica,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Results of human islet allotransplantation in cystic fibrosis and type I diabetic patients.
March 1998, Transplantation proceedings,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Simultaneous solid organ, bone marrow, and islet allotransplantation in type I diabetic patients.
December 1994, Transplantation proceedings,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Prediction of clinical outcome in islet allotransplantation.
February 2007, Diabetes care,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Human islet allotransplantation with Basiliximab in type I diabetic patients with end-stage renal failure.
May 2002, Transplantation proceedings,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Human islet allotransplantation in 18 diabetic patients.
June 1992, Transplantation proceedings,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients within the Swiss-French GRAGIL network.
April 2004, Transplantation,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
[Effect of pancreatic islet cell culture allotransplantation on the clinical course of proliferative diabetic retinopathy].
January 1989, Problemy endokrinologii,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
On the variability of outcome after islet allotransplantation.
June 1988, Transplantation,
A Secchi, and C Socci, and P Maffi, and L Falqui, and F Bertuzzi, and P De Nittis, and L Piemonti, and M V Taglietti, and V Di Carlo, and G Pozza
[Clinical allotransplantation of human fetal islet cell cultures].
January 1985, Problemy endokrinologii,
Copied contents to your clipboard!